Clinica Universidad de Navarra (Navarra Hospital)
Chemotherapy for esophageal carcinoma in Spain typically costs from $3,500 to $7,000. The final price depends on the drug regimen and the required number of cycles. In the United States, similar treatments cost around $25,000 on average. Patients in Spain save approximately 79% compared to US rates. Quotes usually include consultations, medication, blood work, and nursing care.
Bookimed Expert Insight: Choosing a facility within a large network offers unique financial and clinical advantages. Hospital HM Nou Delfos belongs to the largest medical network in Spain. This ensures access to shared tumor board reviews and standardized pricing. Patients should also consider Clinica Universidad de Navarra, which is accredited by JCI. This hospital has been named the best private facility in Spain. They provide high-level care that often justifies slightly higher regional costs in Pamplona.
| Turkey | Austria | Spain | |
| Chemotherapy for esophageal carcinoma | from $5,000 | from $12,000 | from $3,500 |
No hidden fees – just official clinic prices. Pay at the clinic for Chemotherapy for esophageal carcinoma upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Chemotherapy for esophageal carcinoma and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Chemotherapy for esophageal carcinoma journey.
Day 1
Day 2
Day 3
Day 4
Week 2
Week 3 - Week 6
Week 7
Week 8 onwards
Please note that each patient"s journey with chemotherapy is unique and can vary based on individual circumstances and responses to treatment.
Medical Director of the University of Navarra Clinic
Prof. of hematology and hemotherapy
Dr. Joan Albanell Mestres is a leading oncologist who specializes in breast cancer. He earned his MBBS from the University Autónoma de Barcelona in 1989. He leads the breast cancer program at HM Delfos and oversees Oncology services at Clin del Mar in Spain.
Dr. Albanell has published 120 scientific articles, with over 9,000 citations. He directs cancer research at Del Mar. He is also an active member of GEICAM, CIBERONC, AIECA, and SEOM. He regularly contributes to important oncology research.